Evaluation of perinatal outcomes in intrahepatic cholestasis of pregnancy

Abstract

Introduction: This study aimed to retrospectively evaluate the perinatal outcomes of the cases followed up in our clinic for Intrahepatic cholestasis of pregnancy (ICP). Methods: In this study, the medical records of 71 patients who applied to Sakarya University Training and Research Hospital, Gynecology and Obstetrics Clinic between April 2015 and March 2021 and were diagnosed with ICP were analyzed retrospectively.Results: The mean age of the patients was 28.9±4.8 years. At the time of diagnosis, the mean week of gestation was 31.9±2.4 weeks, and the mean week of gestation at birth was 36.7±1.5 weeks. It was determined that 20 (28.2%) of the patients had preterm birth before 37 weeks of gestation. The gestational week at the time of diagnosis was found to be statistically significantly lower in patients who had preterm birth (30.5±1.7) compared to those who did not (32±2.5) who did not have preterm birth (p:0.025). When the correlation analysis was performed, a statistically significant negative correlation was found between the gestational week at the time of diagnosis and preterm birth (p=0.024, r=−0.268). Discussion and Conclusion: Although ICP is a benign condition for the mother, it can cause significant complications in the fetus. Therefore, early diagnosis and active management are essential in reducing adverse complications related to ICP.

A Systematic Review On Complications of Intrahepatic Cholestasis of Pregnancy

“…Ursodeoxycholic acid is a tertiary bile acid found in small concentrations in normal human serum and used to treat ICP (Gök et al, 2022a). Though it is not approved for use during pregnancy, it treats intrahepatic pregnancy cholestasis.…”